---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-010139"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:26:11.458929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine names Erick Lucera as CFO, replacing Michelle Robertson

## Summary
- Erick Lucera appointed EVP and CFO effective May 17, 2023, succeeding Michelle Robertson who stepped down May 16.
- Lucera previously CFO at AVEO Pharma; receives $470k base salary, 45% target bonus, and equity grants.
- Equity includes option for 155,800 shares, RSU for 77,900 shares, and performance-based PSU for 77,900 shares.
- Robertson will transition through Aug 16, 2023, receiving 12 months base salary and COBRA contributions.
- Robertson's vested stock option exercise period extended to Aug 16, 2024; release agreement required.

## SEC filing metadata
- accession: 0001558370-23-010139
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/edit-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-010139
- JSON: https://secwatch.observer/filing/0001558370-23-010139.json
- Plain text: https://secwatch.observer/filing/0001558370-23-010139.txt

## Key facts
- Executive change
  Erick J. Lucera was appointed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: On May 16, 2023, Editas Medicine, Inc. (the “Company”) appointed Erick J. Lucera as Executive Vice President and Chief Financial Officer of the Company, effective May 17, 2023, succeeding Michelle Robertson as Executive Vice President and Chief Financial Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm
- Executive change
  Michelle Robertson departed as Executive Vice President and Chief Financial Officer at Editas Medicine, Inc..
  - Action: stepped down
  - Role: Executive Vice President and Chief Financial Officer
  source text: who stepped down as the Company’s Chief Financial Officer effective May 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023010139/0001558370-23-010139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.